- Home
- DTSS vs BIAF Comparison
DTSS vs BIAF Comparison
Compare DTSS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- BIAF
- Stock Information
- Founded
- DTSS 2014
- BIAF 2014
- Country
- DTSS China
- BIAF United States
- Employees
- DTSS N/A
- BIAF N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DTSS Technology
- BIAF Health Care
- Exchange
- DTSS Nasdaq
- BIAF Nasdaq
- Market Cap
- DTSS 16.5M
- BIAF 14.5M
- IPO Year
- DTSS N/A
- BIAF 2022
- Fundamental
- Price
- DTSS $2.10
- BIAF $0.68
- Analyst Decision
- DTSS
- BIAF Strong Buy
- Analyst Count
- DTSS 0
- BIAF 1
- Target Price
- DTSS N/A
- BIAF $6.00
- AVG Volume (30 Days)
- DTSS 64.0K
- BIAF 313.4K
- Earning Date
- DTSS 02-11-2025
- BIAF 11-14-2024
- Dividend Yield
- DTSS N/A
- BIAF N/A
- EPS Growth
- DTSS N/A
- BIAF N/A
- EPS
- DTSS N/A
- BIAF N/A
- Revenue
- DTSS $38,176,218.00
- BIAF $9,367,785.00
- Revenue This Year
- DTSS N/A
- BIAF $285.51
- Revenue Next Year
- DTSS N/A
- BIAF $20.05
- P/E Ratio
- DTSS N/A
- BIAF N/A
- Revenue Growth
- DTSS 262.84
- BIAF 2813.87
- 52 Week Low
- DTSS $1.42
- BIAF $0.66
- 52 Week High
- DTSS $20.29
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- DTSS 42.01
- BIAF 26.89
- Support Level
- DTSS $2.07
- BIAF $0.67
- Resistance Level
- DTSS $2.38
- BIAF $1.01
- Average True Range (ATR)
- DTSS 0.23
- BIAF 0.08
- MACD
- DTSS -0.01
- BIAF -0.01
- Stochastic Oscillator
- DTSS 12.50
- BIAF 4.29
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.